A non‑invasive prenatal test (NIPT) is a maternal blood test, usually offered from about 10 weeks’ gestation, that analyzes cell‑free fetal DNA to screen for common chromosomal conditions such as Down syndrome (trisomy 21), trisomies 18 and 13, and can indicate fetal sex and Rh status. It poses no miscarriage risk but is a screening—not diagnostic—so positive results should be confirmed by invasive testing.

In India, non‑invasive prenatal testing (NIPT) typically costs between ₹12,000 and ₹25,000 for standard trisomy screening. Broader or genome‑wide panels (microdeletions, sex‑chromosome analysis or expanded testing) can run ₹30,000–₹50,000 or more. Final price varies by lab, test panel, turnaround time and city; insurance coverage is uncommon, so confirm exact costs with your chosen provider.

Doctors suggest noninvasive prenatal testing (NIPT) because it analyzes cell‑free fetal DNA from maternal blood to screen early (from about 10 weeks) for common chromosomal abnormalities—especially Down syndrome (trisomy 21), trisomy 18 and 13. It offers high sensitivity and specificity, is noninvasive, helps when maternal age or other screens/ultrasound are abnormal, and can reduce invasive diagnostic tests; positives need confirmation.

NIPT is typically offered from 10 weeks of pregnancy onward. A maternal blood sample taken after 10 weeks usually provides sufficient fetal DNA for reliable screening. Many providers recommend testing between 10 and 14 weeks for optimal results, though it can be performed later if needed. Positive or high‑risk NIPT results should be confirmed with diagnostic testing (CVS or amniocentesis).

NIPT costs vary by country and provider: in the US it’s typically $800–$2,000 out‑of‑pocket (sometimes reduced by insurance), in the UK private tests run about £400–£900 (NHS offers testing for high‑risk pregnancies), and in India roughly ₹10,000–₹30,000. Prices depend on the lab, the panel tested, and whether insurance or national programs cover it. Ask your provider what’s included.

Yes. NIPT analyzes cell-free fetal DNA in maternal blood and can detect Y‑chromosome fragments to indicate fetal sex, usually from about 9–10 weeks gestation. Sex prediction is highly accurate (around 95–99%) but not 100%. Errors can occur with low fetal fraction, a vanishing twin, or maternal transplant. NIPT is a screening test; diagnostic tests or ultrasound can confirm.